| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: NRMX |
| Security Type |
Common Stock |
| Lead Underwriter |
UBS Investment Bank |
| Days In Registration |
28 |
| Date Filed |
20-Aug-2003 |
| Form Filed | F-10 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Neurochem Inc, located in Laval, Quebec is a biopharmaceutical company focused on products to treat neurological diseases. |
| Revenue |
- |
| Net Income |
-$23.3M |
| Shares Outstanding (post-offering) |
28.69M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
4.2M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.2M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$43.72M |
| File Price Range |
$10.41 - $10.41 |
| File Mid Price |
$10.41 |
Current Filing Information
(Amended 17-Sep-2003) |
|
US |
|
Shares Filed |
4.2M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.2M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$45.36M |
| · % Change from Original |
3.75 |
| File Price Range |
$10.80 - $10.80 |
| File Mid Price |
$10.80 |
|
